AB-110 not checked

Antlia Bioscience, Inc

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Hypertension (HTN)
Main trialPhase 1
“This Phase 1, randomized, double-blind study is designed to evaluate safety, tolerability, PK, and PD effects of AB-110. This study will be conducted in 2 parts: a single ascending dose (SAD; Part A) in healthy participants with an optional cohort of BMI \> 30 kg/m2 and ≤ 35 kg/m2 and multiple ascending dose (MAD; Part B) in participants with hypertension who are otherwise healthy. Sentinel dosing will be applied in the Part A study at each new dose level to ensure participant's safety. The study will provide initial insight into the safety and tolerability of AB-110. In addition to safety,…”In the company’s words, NCT07916961 on ClinicalTrials.gov

Other drugs for Hypertension (HTN)

All 73 drugs for Hypertension (HTN)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Not yet recruiting Sep 2027 Study of AB-110 in Healthy and Hypertensive Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow AB-110

Following is part of Solo: you see every change to AB-110 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in